developed

Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer’s Disease

Tokyo June 05, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that in the 8th meeting of the…

5 years ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420